MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
News|Articles|November 2, 2001
- Pharmaceutical Technology-11-02-2001
- Volume 25
- Issue 11
Filter Integrity Testing in Liquid Applications, Revisited Part II
In the concluding part of this article, the authors address diffusive-airflow imprecisions and measurements as well as automated integrity-test equipment, variations in bubble-point measurements, and the identification of a "sterilizing" filter.
Advertisement
Articles in this issue
almost 25 years ago
blankalmost 25 years ago
Truth in Outsourcingalmost 25 years ago
Manufacturers Face Challenges and Regulatory Changesalmost 25 years ago
One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluationalmost 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
2
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
3
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
4
First-in-Human Trial Speed: Why FDA Trails China
5